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Abstract: Patients with rheumatic conditions often suffer from related chronic pain. When first-line traditional medications such as
acetaminophen and anti-inflammatory medications do not suffice, then other options are needed. The traditional medications may
ultimately not provide sufficient pain relief, or alternatively, they can pose as a contraindication due to underlying hypertension, renal,
and/or hepatic disease. Therefore, narcotics are an alluring alternative, which if used in a multidisciplinary and systematic approach to
the patient, can prove to be quite beneficial in the lives of these patients.
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Introduction

The management of chronic pain is a challenge for
physicians, who, in the best interest of their patients,
desire to minimize side effects from pain relieving
medications and who, in the name of humanity,
concurrently seek to provide as much pain relief as
possible. Other than prescribing lifestyle changes,
such as weight loss, physical therapy, yoga, meditation, and exercise, doctors have a limited arsenal
with which to address chronic pain. Such nonpharmacologic and self-management approaches to pain
are indeed important complementary modalities,
which can help amplify therapeutic effects of pharmacologic aids. Acetaminophen and nonsteroidal
anti-inflammatory drugs (NSAIDs) are commonly
invoked as first-line medications in treating musculoskeletal pain. However, when these are ineffective or
cause adverse side effects or otherwise become contraindicated, then opioid analgesics may be beneficial
alternatives.1 Indeed, there are now official guidelines
available from professional societies, (such as the
American Pain Society), regarding incorporation of
opioids in the management of patients with chronic
noncancer pain.2
Among the driving forces behind a renewed interest in opioids for the management of muscluloskeletal pain are the many potential adverse effects of
NSAIDs. For example, conditions typically afflicting
older patients such as osteoarthritis and back pain are
often treated with NSAIDs. But for many reasons, this
same population may be especially prone to potential
adverse effects on blood pressure, renal function, the
gastrointestinal tract, and the cardiovascular system.3
For example, one recent Cochrane review concluded
that NSAIDs should be used cautiously in patients
with chronic inflammatory arthritis who have a history of gastrointestinal comorbidity.4 Interestingly,
topical NSAIDs have been shown to play a more
benign role, compared with their orally administered
counterparts. The topical route leads to less systemic
concentration of the drug and, hence, to a reduction
in potential side effects.5 However, a meta-analysis of
the efficacy of topical nonsteroidal anti-inflammatory
drugs in osteoarthritis observed that topical NSAIDs
were superior to placebo in the first 2 weeks of
treatment but not the following 2 weeks (albeit less
effective than oral NSAIDs).6 Therefore, given the
observed short duration of pain relief and reduced
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potency, alternative therapies are often sought when
treating long-term pain.
Anticonvulsants and antiepileptics are alternative agents sometimes employed for the treatment of
chronic pain.7 Although these drugs may have less
adverse impact on renal and gastric function, they
carry an increased risk of neurological side effects as
well as potential arrhythmogenic properties. Clearly,
there exists a significant need for alternative modalities for the management of chronic noncancer pain.8
This review will revisit the use and side effects of
opiates for rheumatological conditions. It will not,
however, address nonstandard interventions such as
cannabinoids, which have been reviewed elsewhere.

Justification

Opioids have an established role in the therapeutic
armamentarium for rheumatic diseases. Primarily,
they are employed for short-term use or as temporizing therapy until definitive surgical intervention is
achieved.9 Recently, longer term use of these agents is
gaining support in chronic degenerative conditions.10
Properly used, opiates may improve function. For
example, walking speed may improve in patients taking opiates for osteoarthritis of the knee.11 Admittedly,
in a systematic review by Papalionteous et al,12 a small
negative effect of opiates on cognitive function was
noted. However, the authors cannot translate the clinical significance of such a finding, and acknowledge
that this appears contradictory to other papers in their
review, which found no such effect.
Furthermore, The American Geriatric Society has
extensively reviewed opioid use in elderly. Their
guidelines advise physicians to clearly consider opioids if patients still have daily physical limitations,
moderate to severe pain, or pain-related suboptimal
quality of life, and who have failed acetaminophen
use.13 This notion is further supported as per the World
Health Organization recommendations.

Barriers to the Use of Opioids

The causes of underutilization of opiates by physicians
in the treatment of noncancer pain are myriad, including common fears of addiction, respiratory depression,
and pharmacological tolerance.11 However, the actual
risk of addiction seems to be fairly small: 3% to 18%
in various reports, with an average approximate risk
of 10% in those on chronic opiate therapy. In a focus
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group of physicians who expressed their apprehensions regarding opiod therapy in elderly, a fear of
causing harm was the most commonly cited reason.
Pain subjectivity and exaggeration of the amount
of pain was also a common concern. Interestingly,
patient-perceived barriers included a reluctance to try
opiates secondary to concern for costs, side effects,
potential for addiction, as well as stigma in society
associated with narcotic use.14
A
meta-analysis
assessing
psychotropic
medications and the risk of fracture showed that
regarding opioid medications, there exists a moderate
but significant increase in the risk (38%) of fractures.15
This finding, along with the known risk of increased
falls in the elderly, such as falls that may arise purely
from progressive cognitive decline, is another wellestablished barrier to prescribing narcotics for the
elderly. Perhaps periodic and consistent cognitive
assessment schedules should be implemented for
patients on long-term opioids. This can potentially
identify and rectify new or rapid declines before they
result in an incident.
Opioid-induced hyperalgesia (OIH) is another
potential concern in which the patient’s perception
of pain worsens due to long-standing opioid use.
The mechanism for this event is not entirely lucid,
but a popular theory involves an accumulation of
inactive opioid metabolites competitively obstructing
the analgesic effects of the active metabolites on
µ receptors. Another hypothesis behind the amplification of pain has to do with activation of the descending pain pathways (rostral ventromedial medulla) via
enhanced concentration of neurotransmitters such as
cholecystokinin and N-methyl-D-aspartate.16 As a
result of activation of these descending tracts, there
is increased sensitivity to pain. Although it is difficult to tease apart opioid tolerance from OIH, there
are some differences. For example, with tolerance,
the location and nature of the pain remains the same.
However, in OIH, the pain takes on a more generalized form, as opposed to more focal, and the intensity may be worse than the initial pain symptoms.
Overall, in OIH, the patient is sensitive to even minor
painful phenomenon, and the patient’s threshold for
pain decreases. Furthermore, other generalized neuroexcitatory symptoms, including agitation, seizures,
and even delirium have been reported.16 It is important to note that this is a relatively rare occurrence and
Health Services Insights 2013:6

that often an appropriate multidisciplinary approach
to the patient prevents such a side effect.
Finally, it should be emphasized that research on
therapeutic effectiveness of various agents in general
requires valid and reliable measures of pain. Since
subjective assessments are a barrier to evaluating
the efficacy of various pain management modalities,
researchers commonly supplement pain assessments
with functional assessments.

Opioids and Functional Assessment

Tens of millions of patients are affected by some form
of arthritis. Although various modalities of treatment
do exist, objective assessment tools for evaluation
of the efficacy of specific modalities remain crude.11
Recently, a gait-related marker has been investigated
as a potential objective assessment tool. This is
because normal ambulatory mechanics are altered
when patients experience pain from knee osteoarthritis (OA). A common gait adjustment in response to
pain is a reduction in the speed of walking. In one
study, Boyer et al11 evaluated ambulatory mechanics in knee OA patients who were on NSAIDs versus
those on opioids. Overall, both groups demonstrated
improved walking speeds, suggesting noninferiority
of opioids in this situation despite their lack of
anti-inflammatory benefit. Although the NSAID
group manifested significant improvement in knee
joint mechanics, in patients with contraindications
to NSAID use (that is, recent gastrointestinal bleeding, renal failure, heart failure, etc.), opiates provide
a plausible alternative therapy.17

Nociceptive Effects of Opioids

Opioid-induced hyperalgesia (OIH) has been described
as increased sensitivity to stimuli that normally provoke pain or exacerbation of pain in the absence of
new tissue damage.18 OIH has been seen to develop
after prolonged exposure to opioids and is defined as
a state of nociceptive sensitization.19 Although it has
been described in medical literature since 1800, the
incidence is still unknown and the diagnosis remains
difficult to secure. Clinically, OIH manifests as hyperesthesia or allodynia and may be accompanied by other
signs of opioid toxicity (eg, myoclonus, delirium,
and seizures). Commonly, patients report worsening
pain despite increasing doses. Typically, the worsening pain cannot be explained by progression of the
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original condition.20 Morphine is the most common
offending agent.21 The precise molecular mechanism
of OIH, while not yet understood, is generally thought
to result from neuroplastic changes in the peripheral
and central nervous system (CNS) that lead to sensitization of pronociceptive pathways. While there
are many proposed mechanisms, those involving
the central glutaminergic system, spinal dynorphins,
descending facilitation, and genetics have been
highlighted. Of these, the central glutaminergic system is considered the most likely possibility. Other
hypotheses invoke N-methyl-D-aspartate (NMDA)
receptors, inhibition of the glutamate transporter system, facilitation of calcium-regulated intracellular
protein kinase C, and cross talk of neural mechanisms
of pain and tolerance.19
It is also possible that lack of effectiveness with
opioids may be more common than anticipated.
Traditional interventions for OIH include opioid rotation, reduction of the administered dose, detoxification,
and use of nonopioid and adjuvant analgesics.19,21 As
previously noted, a major dilemma resides in distinguishing OIH from tolerance. In addition, the clinician must be able to distinguish aggravating factors
to OIH including progression of the original disease
process, new interval injury, and clinical exacerbation
of preexisting pain.19

Non-Nociceptive Effects of Opioids

There may be non-nociceptive effects of opioids on
the immune system as well.22 Opioids interact with
3 known receptors: µ, δ, and κ, which are G-protein
coupled.1 The class of opioids include alkaloids,
synthetic formulations, and endogenous compounds,
which occur naturally within the body. Opioids
function to decrease intracellular calcium levels,
ultimately resulting in reduction in presynaptic neurotransmitter release. Other than analgesic effects,
opioids have been found to exert immunosuppressive effects, speculated to be caused by their molecular structure. CNS-mediated immunosuppressive
effects are related to decreased natural killer cell
activity along with decreased lymphocyte proliferation and interferon gamma secretion. Interestingly,
opioids that do not have the capability to cross the
blood-brain barrier do not exert such immunosuppressive effects.23 The mechanisms with which opioids exert their central effects, (ie, neuroendocrine
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axis via sympathetic nervous system route), remain
unclear.23,24 There are also reports of peripheral
immunomodulating effects of opioids, but this is
a less potent effect as compared with the centrally
mediated pathway.23 For instance, it has been shown
that bone marrow cells exposed to chronic opioid
therapy diminish the ability for macrophage progenitor cells to proliferate upon exposure to macrophagecolony stimulating factor. Furthermore, phagocytic
capabilities of macrophages are compromised as a
result of chronic opioids exposure. Multiple other
inhibitory effects on NK cells, T cells, and inflammatory mediators as a result of opioid exposure,
have been described.23
So, how does this translate into clinical risk of
infection and sepsis in patients who are subjected to
opioid therapy? The answer is not well-established as
there is only a minimal number of outcome studies.
However, it is of paramount importance to note that
pain itself can activate sympathetic systems, thereby
contributing to hemodynamic instability in the critically ill patient. Therefore, adequate analgesia is a
key focus in these patients.23 Furthermore, in rheumatologic conditions such as rheumatoid arthritis, for
example, where an overactive immune system is contributing to pain, patients perhaps may benefit from
the reported immunosuppressive effects of such opiate therapy.
All opioids are not created equal, meaning some
exert more immunosuppressive effects than others.23,24
Based on the results of animal studies, it is known
that morphine, methadone, codeine, and remifentanyl
tend to be more immunosuppressive than buprenorphine, oxycodone, hydromorphone, and tramadol.24
Of interest, however, is an observation that tolerance
may develop against immunosuppressive effects of
opioids, over time.24 This is an area for further scientific exploration.

Specific Modalities

Weak oral opioids such as tramadol may be effective
in the management of chronic pain, but the scientific
evidence for their superiority relative to NSAIDs is
by and large lacking.25 This is as true for the pain
related to rheumatoid arthritis as it is to pain related
to osteoarthritis.25 However, the combination therapy
of tramadol-paracetamol does appear to be effective
in chronic low back pain.26
Health Services Insights 2013:6
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Indeed, novel combination therapies with opioids,
both weak and strong, while popular, in general have
as yet to demonstrate improved function.27
Transdermal delivery systems for opiates are widely
used. Some such agents may have a role to play in
the management of osteoarthritis pain.28 Recent studies with long-acting transdermal buprenorphine have
suggested an improved quality of life in addition to
pain relief in elderly patients (mean age 72.8 years)
with chronic pain.29
Iontophoresis is another drug delivery modality whereby medications are transdermally carried
into the skin by an electrical current.30 It has been
shown that if the current carries the same charge
as the drug of interest, then this helps to carry the
drug deep and deposit it in subcutaneous tissues.30
Fentanyl has been the most studied opioid for iontophoresis and has been shown to reach steady state
fairly quickly.30 Another advantage is that its delivery rate can be varied accordingly.30 Therefore, this
can be of significant benefit to patients with chronic
pain syndromes.
It should be noted here that in addition to the
expected opiate side effects, adverse cutaneous reactions to these delivery systems are common.31
Opioids administered intraarticularly have been
studied. Some reports show intraarticular opioids
to be ineffective; others report a significant positive effect on postoperative analgesia. It may be
that since the degree of postoperative pain varies
from patient to patient, a concerted effort must be
undertaken in order to find the optimal therapeutic regimen. Although many clinical studies have
been published on the intraarticular administration of various agents, morphine is the most commonly used analgesic after major surgery.32 And
although its half life is about 2 hours, when introduced intraarticularly, its analgesic effects may last
24 hours.
Another agent, methadone, is a synthetic longacting anesthetic agent with high activity on opioid receptors and a half-life of about 35 hours. It is
highly bound to plasma protein. After intra-articular
injection of methadone, analgesic effects last for
24 hours. Pethidine is an anesthetic opioid drug
whose half-life is about 4 hours. It has lower affinity to proteins and higher risk of convulsions than
morphine. After intraarticular injection of pethidine,
Health Services Insights 2013:6

the duration of anesthetic effect lasts about 12 hours.33
Tramadol is a weak (selective l receptor) opioid
agonist. An intraarticular admixture of tramadol
with bupivacaine provides a pronounced prolongation postoperative analgesia in patients undergoing arthroscopic knee surgery.34 Some studies have
demonstrated that the intraarticular injection of
bupivacain/fentanyl is also effective, especially so in
the presence of synovitis.35 Finally, some researchers
have suggested that intraarticular administration of
sufentanil alone or in combination with methylprednisolone after knee meniscectomy is effective, reliable, and well tolerated.32
In summary, although a systematic review by
Gupta et al concluded that when compared with placebo, intraarticular morphine does provide analgesic
effects,36 there exists wide variability both between
and within studies regarding the intensity of analgesic properties.36 Hence, it is difficult to extrapolate a
dose-dependent analgesic effect. Therefore, creating
dosing guidelines remains challenging.36

Other novel administration routes

The intranasal route of administration seems to be
promising in multiple situations. For example, it can
be ideal in the preoperative setting as well as for pain
control in the postoperative time period.30 It can be
useful in the pediatric population (eg, in the setting of
the emergency room) after trauma.30 In this situation,
the intranasal form works as well as the intramuscular form and is more acceptable to parents and their
children.30

Conclusions

Overall, there are a wide variety of pain-relieving modalities in the toolbox of rheumatologists,
although these agents fall within several broad categories: anti-inflammatories, acetaminophen-based
agents, narcotics, numbing anesthetics, and newer
experimental agents. Each category has its pluses
and minuses. In the setting of addressing the needs
of rheumatologic patients, recognizing each patient’s
unique requirements is key. In the setting of cardiovascular, gastrointestinal, or renal disease, low dose
opiate therapy is well justified, and has been shown
to be efficacious, even in the older patient. With
proper counseling, a multidisciplinary approach,
and frequent follow-up evaluations, opiates may be
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a viable option in the patient with musculoskeletal
pain.
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